Lates News

Hengrui Medicine announced that its subsidiaries Suzhou Shendia Biopharmaceutical Co., Ltd. and Shanghai Shendi Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration to conduct clinical trials for the injection SHR-A1811, the Adabelli monoclonal antibody injection, and the sorafenib apple acid capsule. The clinical trials will begin soon. The injection SHR-A1811 will be used in combination with anti-tumor drugs for the treatment of solid tumors in an open, multi-center phase Ib/II clinical study. The sorafenib apple acid capsule will be used in combination with the injection of carrizumab monoclonal antibody for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with bevacizumab monoclonal antibody. Up to now, the total research and development investment in the injection SHR-A1811 project is about 1.17 billion yuan, in the Adabelli monoclonal antibody injection project about 815 million yuan, and in the sorafenib apple acid capsule project about 255 million yuan.